New Drug Could Change Lives of Kids with Resistant Epilepsy, Patient Trials Concluded The trial involved 81 children between the ages of 2 and 18 that suffered up to 18 seizures a month resulting from Dravet syndrome

#Zorevunersen, shows that pharmaceuticals can work to improve the lives of patients with these #epilepsies

#UK drug trials in phase 2 clinical trials now.

Original post on mastodon.social

www.theguardian.com/society/2026/mar/04/scie... https://www.dravet.org.uk/ https://www.nejm.org/doi/full/10.1056/NEJMoa2506295 (abstract only). "The lead author Helen Cross... said: 'I regularly see #patients with hard-to-treat #genetic […]

BPS Publications Background and Purpose Pharmacological activation of neuronal M-current mediated by Kv7 (Kv7.2–5) potassium channels is a validated mechanism for epilepsy treatment. However, since the market withdr...

📢 New #publication from our network!
Fraunhofer ITMP used our ECBL pilot library to discover a promising candidate therapy for rare childhood #epilepsies.

📖 Study: bpspubs.onlinelibrary.wiley.com/doi/10.1111/...
📊 Data: ecbd.eu/targets/EOS3...

#EUOPENSCREEN #DrugDiscovery #FAIRdata #chembio

interventions to prevent the development of the disorder are not available. Moreover, in at least 30% of patients, epilepsy cannot be controlled by current antiseizure medications .
About 20% of #epilepsies are caused by CNS injuries such as TBI , stroke cerebrovascular accident & infection